Preethi Krishnan

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Xavier Forns, Samuel S. Lee, Joaquin Valdes et al. · The Lancet Infectious Diseases · 2017 · 343 citations

Medicine, Infectious Diseases, Pharmacotherapy +14

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Tarik Asselah, Kris V. Kowdley, Neddie Zadeikis et al. · Clinical Gastroenterology and Hepatology · 2017 · 230 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Identifying polyglutamine protein species in situ that best predict neurodegeneration

Jason Miller, Montserrat Arrasate, Elizabeth D. Brooks et al. · Nature Chemical Biology · 2011 · 222 citations · Full text

Life Sciences, Molecular Biology, Neuroscience +14

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Nancy Reau, Paul Y. Kwo, Susan Rhee et al. · Hepatology · 2018 · 181 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

David Wyles, Fred Poordad, Stanley Wang et al. · Hepatology · 2017 · 146 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17